Ben Boursi1, Bruce J Giantonio2, James D Lewis3, Kevin Haynes3, Ronac Mamtani2, Yu-Xiao Yang3. 1. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; Tel-Aviv University, Tel-Aviv, Israel. Electronic address: yangy@mail.med.upenn.edu. 2. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. 3. Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Abstract
BACKGROUND: Despite the lack of scientific data, many cancer patients hold the belief that glucose 'feeds' cancer and might affect disease outcome. We aimed to evaluate associations between glucose, hemoglobin A1C (HbA1C), and survival among individuals with diabetes and diabetes associated cancers. METHODS: Five retrospective cohort studies were conducted in a large population-representative database. The study population included all patients with diabetes and an incident diagnosis of colorectal, breast, bladder, pancreatic and prostate cancers. Exposure of interest was serum glucose or HbA1C levels within 6 months prior to cancer diagnosis. Cox regression model was used to calculate hazard-ratio (HR) and 95% confidence-interval (CI) for overall survival. Analyses were adjusted for cancer-specific confounders. A subgroup analysis was performed among insulin-treated patients. RESULTS: Study cohorts included 7916 individuals with incident cancers and concurrent diabetes. There was no association between HbA1C levels and overall survival in colorectal (HR 1.00, 95% CI 0.95-1.06), breast (HR 1.03, 95% CI 0.95-1.11), bladder (HR 0.94, 95% CI 0.86-1.01), pancreatic (HR 0.98, 95% CI 0.94-1.02), or prostate (HR 1.02, 95% CI 0.96-1.08) cancers. Among diabetes patients treated with insulin, there was increased survival with increasing serum glucose, most prominent for bladder cancer (HR 0.91, 95% CI 0.84-0.99, per 1 mmol/l increase). CONCLUSIONS: Higher glucose and HbA1C levels in diabetes patients with incident cancer are not associated with worse overall survival following cancer diagnosis. Among insulin-treated patients, higher glucose levels may be associated with improved survival.
BACKGROUND: Despite the lack of scientific data, many cancerpatients hold the belief that glucose 'feeds' cancer and might affect disease outcome. We aimed to evaluate associations between glucose, hemoglobin A1C (HbA1C), and survival among individuals with diabetes and diabetes associated cancers. METHODS: Five retrospective cohort studies were conducted in a large population-representative database. The study population included all patients with diabetes and an incident diagnosis of colorectal, breast, bladder, pancreatic and prostate cancers. Exposure of interest was serum glucose or HbA1C levels within 6 months prior to cancer diagnosis. Cox regression model was used to calculate hazard-ratio (HR) and 95% confidence-interval (CI) for overall survival. Analyses were adjusted for cancer-specific confounders. A subgroup analysis was performed among insulin-treated patients. RESULTS: Study cohorts included 7916 individuals with incident cancers and concurrent diabetes. There was no association between HbA1C levels and overall survival in colorectal (HR 1.00, 95% CI 0.95-1.06), breast (HR 1.03, 95% CI 0.95-1.11), bladder (HR 0.94, 95% CI 0.86-1.01), pancreatic (HR 0.98, 95% CI 0.94-1.02), or prostate (HR 1.02, 95% CI 0.96-1.08) cancers. Among diabetespatients treated with insulin, there was increased survival with increasing serum glucose, most prominent for bladder cancer (HR 0.91, 95% CI 0.84-0.99, per 1 mmol/l increase). CONCLUSIONS: Higher glucose and HbA1C levels in diabetespatients with incident cancer are not associated with worse overall survival following cancer diagnosis. Among insulin-treated patients, higher glucose levels may be associated with improved survival.
Authors: V Papa; V Pezzino; A Costantino; A Belfiore; D Giuffrida; L Frittitta; G B Vannelli; R Brand; I D Goldfine; R Vigneri Journal: J Clin Invest Date: 1990-11 Impact factor: 14.808
Authors: Ahmed N Dehal; Christina C Newton; Eric J Jacobs; Alpa V Patel; Susan M Gapstur; Peter T Campbell Journal: J Clin Oncol Date: 2011-11-28 Impact factor: 44.544
Authors: Jeffrey A Meyerhardt; Paul J Catalano; Daniel G Haller; Robert J Mayer; John S Macdonald; Al B Benson; Charles S Fuchs Journal: J Clin Oncol Date: 2003-02-01 Impact factor: 44.544
Authors: Paolo Contiero; Franco Berrino; Giovanna Tagliabue; Antonio Mastroianni; Maria Gaetana Di Mauro; Sabrina Fabiano; Monica Annulli; Paola Muti Journal: Breast Cancer Res Treat Date: 2013-04-09 Impact factor: 4.872
Authors: Justin Y Jeon; Duck Hyoun Jeong; Min Geun Park; Ji-Won Lee; Sang Hui Chu; Ji-Hye Park; Mi Kyung Lee; Kaori Sato; Jennifer A Ligibel; Jeffrey A Meyerhardt; Nam Kyu Kim Journal: PLoS One Date: 2013-02-06 Impact factor: 3.240
Authors: Xavier Ruiz-Plazas; Esther Rodríguez-Gallego; Marta Alves; Antonio Altuna-Coy; Javier Lozano-Bartolomé; Manel Portero-Otin; Joan Francesc García-Fontgivell; Salomé Martínez-González; José Segarra; Matilde R Chacón Journal: J Transl Med Date: 2019-09-09 Impact factor: 5.531